• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract Addition of daratumumab to standard of care improves minimal residual disease negativity in patients with newly diagnosed, transplant-ineligible multiple myeloma

byKathleen Lau
July 23, 2021
in StudyGraphics
0
Share on FacebookShare on Twitter

RELATED REPORTS

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

2 Minute Medicine Rewind, May 16

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

Tags: bloodblood cancerbortezomibcancerdaratumumabdexamethasonehematologylenalidomidemelphalanminimal residual diseasemultiple myelomanewly diagnosed multiple myelomaoncologyprednisone
Previous Post

Automated behavioral intervention for improving workplace diet did not prevent weight gain

Next Post

Adjuvant celecoxib not associated with improved disease-free survival in patients with ERBB2-negative breast cancer

RelatedReports

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
StudyGraphics

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

May 19, 2022
Image-guided percutaneous drainage of pericardial effusions is safe and effective
Weekly Rewinds

2 Minute Medicine Rewind, May 16

May 16, 2022
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

May 11, 2022
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Cardiology

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

May 3, 2022
Next Post

Adjuvant celecoxib not associated with improved disease-free survival in patients with ERBB2-negative breast cancer

Abusive head trauma results in fewer productive life-years

Computed tomography findings may be useful in prognostication for mild traumatic brain injury

Home health management of patients undergoing deep brain stimulation for Parkinson’s disease is safe and feasible

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.